A Randomized Double-Blind Phase II Trial of Celecoxib, a COX-2 Inhibitor, in the Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3 (CIN 2/3 or CIN 3).
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Celecoxib (Primary)
- Indications Cervical cancer; Cervical intraepithelial neoplasia
- Focus Adverse reactions; Therapeutic Use
- 15 Sep 2017 Biomarkers information updated
- 25 Apr 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 29 Sep 2010 Status changed from suspended to recruiting as reported by ClinicalTrials.gov.